Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study

BACKGROUND: Topoisomerase is an essential enzyme for deoxyribonucleic acid replication, and its inhibitors suppress tumor progression. Amrubicin, a topoisomerase II inhibitor, is mainly used in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). However, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Uda, Sayaka, Yamada, Tadaaki, Yoshimura, Akihiro, Goto, Yasuhiro, Yoshimine, Kohei, Nakamura, Yoichi, Shiotsu, Shinsuke, Yokoi, Takashi, Tamiya, Nobuyo, Kimura, Hideharu, Chihara, Yusuke, Umeda, Yukihiro, Izumi, Miiru, Takeda, Takayuki, Yamada, Takahiro, Hibino, Makoto, Hiranuma, Osamu, Ito, Kazuhiro, Okada, Asuka, Osugi, Shuji, Takemura, Yoshizumi, Ishii, Hiroshi, Chibana, Kenji, Hasegawa, Isao, Morimoto, Yoshie, Iwasaku, Masahiro, Tokuda, Shinsaku, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554692/
https://www.ncbi.nlm.nih.gov/pubmed/36248326
http://dx.doi.org/10.21037/tlcr-22-160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554692/
https://www.ncbi.nlm.nih.gov/pubmed/36248326
http://dx.doi.org/10.21037/tlcr-22-160

Ejemplares similares